369 related articles for article (PubMed ID: 30849971)
1. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis.
Zhang L; Liang Y; Li S; Zeng F; Meng Y; Chen Z; Liu S; Tao Y; Yu F
Mol Cancer; 2019 Mar; 18(1):36. PubMed ID: 30849971
[TBL] [Abstract][Full Text] [Related]
2. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
[No Abstract] [Full Text] [Related]
5. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA as a post-treatment surveillance strategy: current status.
Burgener JM; Rostami A; De Carvalho DD; Bratman SV
Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
[TBL] [Abstract][Full Text] [Related]
7. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
8. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA.
van der Pol Y; Mouliere F
Cancer Cell; 2019 Oct; 36(4):350-368. PubMed ID: 31614115
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.
Rizzo A; Ricci AD; Tavolari S; Brandi G
Cancer Genomics Proteomics; 2020; 17(5):441-452. PubMed ID: 32859625
[TBL] [Abstract][Full Text] [Related]
10. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
11. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA.
Ritch E; Wyatt AW
Urol Oncol; 2018 Aug; 36(8):380-384. PubMed ID: 29248429
[TBL] [Abstract][Full Text] [Related]
12. The clinical role of circulating free tumor DNA in gastrointestinal malignancy.
Howell JA; Khan SA; Knapp S; Thursz MR; Sharma R
Transl Res; 2017 May; 183():137-154. PubMed ID: 28056336
[TBL] [Abstract][Full Text] [Related]
13. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Circulating Tumor DNA.
Mithraprabhu S; Spencer A
Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.
Weerts MJA; Timmermans EC; van de Stolpe A; Vossen RHAM; Anvar SY; Foekens JA; Sleijfer S; Martens JWM
Neoplasia; 2018 Jul; 20(7):687-696. PubMed ID: 29842994
[TBL] [Abstract][Full Text] [Related]
16. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
17. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
18. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
[TBL] [Abstract][Full Text] [Related]
19. Integrating chromatin accessibility states in the design of targeted sequencing panels for liquid biopsy.
Taklifi P; Palizban F; Mehrmohamadi M
Sci Rep; 2022 Jun; 12(1):10447. PubMed ID: 35729208
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications.
Papadopoulos N
Recent Results Cancer Res; 2020; 215():163-180. PubMed ID: 31605229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
